Het placeboeffect is een echt fysiologisch fenomeen. Wanneer iemand verlichting verwacht, door eerdere behandelingen geconditioneerd is en met aandacht wordt verzorgd, schakelen de eigen regulerende systemen van het lichaam in. Een placebo veroorzaakt de afgifte van dopamine bij de ziekte van Parkinson en van de eigen opioïden van het lichaam tegen pijn. Het verklaart een groot deel van de verbetering die mensen ervaren door antidepressiva.
In zorgvuldige proeven verlichtte het moeheid gerelateerd aan kanker, zelfs toen werd verteld dat de pil geen geneesmiddel bevatte. Dezelfde fysiologie werkt omgekeerd bij het nocebo-effect. Wat een placebo beïnvloedt, is hoe iemand zich voelt en functioneert: het laat een tumor niet krimpen, verlaagt geen bloedsuikerwaarde en hecht geen gebroken bot.
Findings & Outcomes
What It Is
A placebo response is an improvement produced by the context of a treatment: the pill, the ritual, the practitioner's attention, and the expectation of getting better. Two mechanisms drive it. Expectation changes what the nervous system does next. Conditioning is learned: pairing a dummy treatment with a real drug effect enough times teaches the body to reproduce part of that effect on its own.
The effect is largest for symptoms the brain itself produces and controls: pain, depression, anxiety, nausea, fatigue, irritable bowel, and the motor symptoms of Parkinson's disease.
A placebo moves how a person feels and functions. It does not shrink a tumor, lower a blood sugar reading, or knit a broken bone.
Two terms get confused, and good research separates them by comparing a placebo group with an untreated group.
- The placebo response is everything that improves after an inert treatment. It includes the illness running its natural course and the tendency of extreme symptoms to drift back toward average, an artifact called regression to the mean.
- The placebo effect is the part caused specifically by expectation and context.
What remains after subtracting the illness's natural course is the placebo effect itself.
What the Evidence Shows
People given a pill openly described as inert, containing no drug, still improved more than people given no treatment. Three open-label trials show the size.
- Irritable bowel syndrome: patients told plainly their pills were placebos scored 5.0 on the IBS Global Improvement Scale, a 1-to-7 scale, over three weeks. An untreated group scored 3.9.
- Chronic low back pain added to usual care: composite pain dropped 1.5 points on a 0-to-10 scale, against 0.2 with usual care alone.
- Cancer survivors: fatigue fell by about 29% from baseline.
Pooling 11 of these open-label trials across conditions gave a significant overall effect, a standardized mean difference of 0.72 (von Wernsdorff 2021). The trials are mostly small, short, and measured by self-reported scales, so the long-term size of the effect is not known. The benefit is clearest for brain-mediated symptoms.
The pattern extends to depression. In an analysis of the antidepressant trial data submitted to US regulators, most of the improvement people got on the drugs was matched by improvement on placebo. The drug–placebo gap was clear only in the most severely depressed patients, mostly because the placebo response was weaker there.
The Research & Studies
Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.
Mood & stress
Placebo matched most of the antidepressant response, the drug ahead mainly in severe depression
In depression trials, most of the improvement people got on antidepressants also happened on placebo. The drug clearly outperformed placebo mainly in the most severe cases, where the placebo response was smaller.
A meta-analysis of clinical-trial data submitted to the US regulator (including unpublished trials) examined how the antidepressant-versus-placebo difference varied with baseline severity. Both drug and placebo groups improved substantially; the difference between them met a standard threshold for clinical significance only at the highest severity levels, and this widening gap was driven mostly by a diminishing placebo response in severe depression, not a rising drug response. The finding measures how large the placebo component of the response is, not that antidepressants are ineffective.
The study · 1
Kirsch et al. 2008, PLoS Med · PLoS Med
How it works
Het blokkeren van opioïdereceptoren met naloxon heft een groot deel van de placebo-pijnverlichting op
Veel placebo-pijnverlichting berust op de eigen opioïden van het lichaam. Blokkeer die receptoren met een geneesmiddel en de verlichting verdwijnt grotendeels; hersenscans tonen aan dat de placebo hetzelfde pijnbeheersingscircuit gebruikt als morfine.
Twee complementaire onderzoekslijnen stellen het mechanisme vast. Bij postchirurgische tandpijn hief de toediening van naloxon (een opioïdereceptorantagonist) een groot deel van de door placebo veroorzaakte analgesie op, wat wijst op endogene opioïden (Levine 1978). Decennia later toonde functionele MRI in combinatie met naloxon aan dat placebo-analgesie het afdalende opioïdergische pijnmodulerende systeem activeert, van de rostrale anterieure cingulate cortex via het periaqueductale grijs tot de rostrale ventromediale medulla, en dat naloxon zowel de gedrags- als de neurale placeborespons vermindert (Eippert 2009). Samen tonen ze aan dat placebo-pijnverlichting een echt, opioïde-afhankelijk neurobiologisch proces is.
The studies · 2
Levine, Gordon & Fields 1978, Lancet · Lancet
Eippert et al. 2009, Neuron · Neuron
Open-label placebo helped on average across 11 pooled randomized trials
Pulling together the trials where people knew they were taking a placebo, the pills still helped on average across a range of conditions.
A systematic review and meta-analysis reviewed 13 randomized controlled trials of open-label placebo (openly described inert treatment) and pooled 11 of them across a spread of conditions and found a significant positive effect overall in favor of open-label placebo compared with no treatment. Effects were clearest for self-reported, brain-mediated symptoms. The authors note the trials are mostly small, short, and heterogeneous, so the pooled estimate establishes that the effect is real and reproducible without fixing a precise size.
The study · 1
von Wernsdorff et al. 2021, Sci Rep · Sci Rep
A placebo released the brain's own dopamine in Parkinson's disease
When Parkinson's patients thought they were getting their real drug, their brains released dopamine, the very chemical the disease lacks, just from expecting to improve.
Using positron emission tomography with raclopride to index dopamine release, researchers found that placebo administration in patients with Parkinson's disease produced marked release of endogenous dopamine in the dorsal and ventral striatum. The response was linked to the patients' expectation of therapeutic benefit and to activity in reward circuitry. It is a small mechanistic imaging study, and it provided direct biological evidence that a placebo response engages a specific, disease-relevant neurochemical system.
The study · 1
Placebo-effecten zijn echte psychobiologische gebeurtenissen, verschillende mechanismen, geen enkel
De experts die het hele vakgebied samenbrengen, concluderen dat het placebo-effect echte biologie is, gedreven door verwachting en leren, werkend via verschillende hersensystemen, en dat het verschilt van aandoening tot aandoening.
Twee grote reviews consolideren het vakgebied. Een Lancet-review beschrijft placebo-effecten als psychobiologische gebeurtenissen die toe te schrijven zijn aan de therapeutische context, veroorzaakt door verwachting en door klassieke conditionering, en waarschuwt dat ze geen te negeren hinder zijn (Finniss 2010). Een Nature Reviews Neuroscience-review brengt de neurowetenschap in kaart: hoe context en leren gezondheidsuitkomsten vormen, de betrokken opioïde- en dopaminesystemen, individuele variatie, en de nocebo-tegenhanger (Wager 2015). Beide zien placebo als verschillende mechanistisch afzonderlijke processen, geen enkel uniform effect.
The studies · 2
Finniss et al. 2010, Lancet · Lancet
Wager & Atlas 2015, Nat Rev Neurosci · Nat Rev Neurosci
Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.
Nocebo: negatieve verwachting produceert echte symptomen en verergert pijn
Het verwachten van schade kan echte symptomen veroorzaken. Gewaarschuwd worden dat een behandeling pijn of misselijkheid kan veroorzaken, maakt die symptomen waarschijnlijker en intenser, via dezelfde hersensystemen die het placebo-effect aandrijven.
Reviews van de placeboliteratuur documenteren de nocebo-tegenhanger: verbale suggestie van een negatieve uitkomst, of eerdere negatieve ervaring, veroorzaakt verergering van symptomen, waaronder toegenomen pijn (hyperalgesie), misselijkheid en vermoeidheid, met meetbare veranderingen in cholecystokinine, dopaminerge en andere routes. Een praktisch gevolg is dat een groot deel van de bijwerkingen die patiënten rapporteren bij actieve medicatie ook voorkomt in de placebogroepen van onderzoeken, wat wijst op een door verwachting gedreven component. Het nocebo-effect toont aan dat het mechanisme bidirectioneel is.
The studies · 2
Wager & Atlas 2015, Nat Rev Neurosci · Nat Rev Neurosci
Finniss et al. 2010, Lancet · Lancet
Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.
Nocebo accounts for about 90% of statin side-effect burden (SAMSON crossover trial)
People who had quit statins over side effects took the real drug, a dummy pill, and nothing in random months. Their symptoms were nearly as bad on the dummy pill as on the statin, so about 90% of what they blamed on the drug also happened on the placebo.
The SAMSON trial gave 60 participants who had abandoned statins twelve one-month bottles: four of atorvastatin 20 mg, four of placebo, and four empty, in random order, with daily symptom intensity logged in an app. Forty-nine completed the 12-month protocol. Symptom scores were much higher than baseline both on the statin (16.3) and on the placebo (15.4) than in no-tablet months (8.0), and the statin and placebo did not differ (P=0.388), giving a nocebo ratio of 0.90. Neither the intensity of symptoms on starting nor their relief on stopping distinguished statin from placebo. Six months after the trial, half the participants had restarted statins. It shows most of the symptoms attributed to a real drug can be nocebo, driven by expectation, not the chemical.
Who this may not transfer to:Enrolled adults of both sexes who had stopped statins over side effects; the nocebo mechanism is not thought to be sex-specific.
The studies · 2
Howard et al. 2021, J Am Coll Cardiol · J Am Coll Cardiol
Wood et al. 2020, N Engl J Med · N Engl J Med
Digestion
Open-label placebo eased IBS more than no treatment (5.0 vs 3.9 improvement score)
People who were told plainly their pills were placebos, with no drug in them, still felt noticeably better than people given nothing, over three weeks with a hard-to-treat gut condition.
A randomized controlled trial in 80 patients with irritable bowel syndrome compared an open-label placebo, presented openly as inert pills with an explanation that placebos can produce powerful mind-body self-healing effects, against a no-treatment control receiving the same clinician attention. After three weeks the open-label placebo group scored significantly higher on the IBS Global Improvement Scale (5.0 vs 3.9, p=0.002) and were more likely to report adequate symptom relief (59% vs 35%). It is a small, short trial in a symptom that reports subjectively, and it is the foundational demonstration that placebo effects do not require deception.
The study · 1
Kaptchuk et al. 2010, PLoS One · PLoS One
Pain
Open-label placebo cut chronic back pain about 30% on top of usual care
People with long-term back pain who added a pill they were told was a placebo, on top of their normal care, had less pain and could do more than those on normal care alone, over three weeks.
A randomized controlled trial in 97 patients with chronic low back pain compared three weeks of open-label placebo added to treatment as usual against treatment as usual alone. The open-label placebo, presented openly as inert, produced significant reductions in composite pain (about 30% in both usual and maximum pain) and in Roland-Morris disability, compared with little change in the usual-care arm. A follow-up in which the control group later crossed over to open-label placebo saw similar improvements. It is a small, short trial with self-reported outcomes.
The study · 1
Carvalho et al. 2016, Pain · Pain
Energy And Fatigue
Open-label placebo eased cancer-related fatigue about 29%
Cancer survivors who took a pill openly labeled as a placebo felt less worn out and coped better than those given no extra treatment, over three weeks.
A randomized controlled trial in 74 cancer survivors with persistent fatigue compared three weeks of open-label placebo against treatment as usual. The placebo group reported significantly greater improvement in fatigue severity (about 29%) and in fatigue-disrupted quality of life. Control participants who then took open-label placebo for three weeks showed comparable gains. The trial is small and short, and fatigue is a subjective outcome, but it extends the open-label placebo finding to a distressing symptom in a serious illness.
The study · 1
Hoenemeyer et al. 2018, Sci Rep · Sci Rep
Immune Function
Het immuunsysteem leerde zichzelf te onderdrukken op een geconditioneerd signaal
Mensen die meerdere keren een immuunonderdrukkend geneesmiddel innamen samen met een ongewoon smakende drank, zagen later hun immuunactiviteit dalen door de drank alleen. Hun lichaam had de reactie aangeleerd.
In een gecontroleerd experiment kregen gezonde mannen het immunosuppressieve geneesmiddel ciclosporine A samen met een nieuw smakende drank tijdens een initiële leerfase. Bij latere hernieuwde blootstelling aan alleen de drank, zonder het geneesmiddel, vertoonden ze onderdrukte immuunfunctie, inclusief verminderde interleukine-2- en interferon-gamma-mRNA-expressie en verminderde lymfocytenproliferatie, vergeleken met controles. Dit toont aan dat een placeborespons in het immuunsysteem kan worden geconditioneerd, een van de twee kernmechanismen (naast verwachting) achter placebo-effecten.
Who this may not transfer to:The immune-conditioning trial enrolled only men; the conditioning mechanism is not thought to be sex-specific, but it was not measured in women.
The study · 1
Goebel et al. 2002, FASEB J · FASEB J
How It Works
The mechanisms are concrete, mapped across the nervous, endocrine and immune systems, and each is graded at the strength of its own evidence.
How a Placebo Acts on the Body
1Expectation changes what the brain does next
Expecting relief switches on specific brain systems that then act on the body. Believing a treatment will help changes what the nervous system does next. That is why the pill, the attention, and the setting matter, and why a confident explanation works better than a doubtful one.
2The pain relief runs on the body's own opioids
For pain, expectation recruits the body's own opioids, the endogenous opioids. Naloxone, which blocks opioid receptors, cancels much of placebo pain relief. Imaging shows placebo analgesia running through the same descending pathway opioid drugs use (the anterior cingulate, the periaqueductal gray, the brainstem.
3Placebo triggers dopamine release in Parkinson's
In Parkinson's, a placebo the person believes is their medication triggers dopamine release in the striatum) the neurotransmitter the disease depletes. PET scans measure it directly, and it tracks the expectation of relief.
4The body can learn a response
Conditioning is the second route. Healthy volunteers who repeatedly took an immune-suppressing drug alongside a distinctive drink later showed immune suppression from the drink alone, the body having learned the response. The reviews describe two routes working together: expectation and learning.
A calm, attentive practitioner and a clear, positive account raise expectation; a rushed or alarming one lowers it. How a treatment is framed changes its effect in the body.
The Nocebo Side
The same mechanism runs in reverse: a negative expectation produces symptoms. Being warned a treatment may cause nausea, pain or fatigue makes those symptoms more likely and more intense, through the same brain and hormone systems.
A blinded crossover trial makes the size plain. Sixty people who had stopped statins over side effects took atorvastatin, a placebo, and nothing across random months, rating symptoms daily (SAMSON 2021). Symptom scores ran much higher on statin than in the no-tablet months, and just as high on placebo, with no difference between drug and dummy. About 90% of the symptom burden they blamed on the statin also appeared on the placebo. This is why a large share of side effects reported on any drug also show up in the placebo arms of its trials.
What This Means For You
Expectation and the ritual of treatment are part of how nearly every therapy works, whether or not the drug is active, and the setting shapes the outcome.
- A treatment you trust, taken as a deliberate act with attention, gives its active part the best chance to work and adds an effect of its own.
- Open-label trials show the benefit survives being told the pill is inert, so candor and effect can go together.
- How a risk is described changes how much of it a person actually feels: a calm, accurate warning produces fewer symptoms than an alarming one.
None of this replaces an effective treatment. A placebo can ease symptoms and improve how someone functions. Calling a benefit "just placebo" is a category error: the placebo effect is a documented self-healing response, with effects on pain, mood, movement and the immune system.
Go Deeper
For how we weigh evidence like this, see how we grade evidence. For how we treat practices that are far older than the studies now testing them, see Yang Sheng and why we built this.
Common Questions
Is the placebo effect real, or just in my head?
It is real, and the brain is part of the body, so "in your head" does not make it less physical. PET scans and naloxone blockade show measurable changes in brain chemistry and hormones.
Can a placebo work if you know it is a placebo?
Yes. People handed a pill and told plainly it held no drug, with an explanation that placebos can act through mind-body pathways, still improved more than untreated people. Deception is not the active part.
Is acupuncture just a placebo?
Trials comparing real acupuncture with sham needling often find both help more than no treatment. The gap between real and sham is usually small and varies by condition, a sign of a placebo component. That does not empty acupuncture of value, and whether needling adds a specific effect on top is measured separately, case by case.
Explore Related
Other pages this one connects to, by the evidence they share, the outcomes they touch, and the ground they cover.
All 15 sources on this page independently checked and cross-referenced.
Thomas Dehli, Founder & Editor, Sacred Lotus
Sacred Lotus has published Chinese medicine reference material since 2001. Integrative pages are held to the same standard as the herb and formula library: cite the source, grade the claim at its real strength, and say where the research has not looked. This page is educational and it is not medical advice. Last reviewed and updated August 10, 2026.
Evidence strength
How confidently the research supports a claim. Strength describes the evidence, not our endorsement.